HRP20230182T1 - Modulatori aktivnosti komplementa - Google Patents
Modulatori aktivnosti komplementa Download PDFInfo
- Publication number
- HRP20230182T1 HRP20230182T1 HRP20230182TT HRP20230182T HRP20230182T1 HR P20230182 T1 HRP20230182 T1 HR P20230182T1 HR P20230182T T HRP20230182T T HR P20230182TT HR P20230182 T HRP20230182 T HR P20230182T HR P20230182 T1 HRP20230182 T1 HR P20230182T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- polypeptide
- concentration
- preparation according
- administered
- Prior art date
Links
- 230000024203 complement activation Effects 0.000 title claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 3
- 239000001488 sodium phosphate Substances 0.000 claims 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 3
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 241000588653 Neisseria Species 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 239000006172 buffering agent Substances 0.000 claims 2
- 229960003405 ciprofloxacin Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 1
- 108090001090 Lectins Proteins 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Steroid Compounds (AREA)
- Amplifiers (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Claims (14)
1. Vodeni farmaceutski pripravak koji sadrži
polipeptid inhibitora C5 koji ima jezgru sekvence SEQ ID NO: 1;
sol; i
pufersko sredstvo.
2. Farmaceutski pripravak prema zahtjevu 1, naznačen time što sol sadrži natrijev klorid.
3. Farmaceutski pripravak prema zahtjevu 1 ili 2, naznačen time što pufersko sredstvo sadrži natrijev fosfat.
4. Farmaceutski pripravak prema zahtjevu 2 ili 3, naznačen time što farmaceutski pripravak sadrži natrijev klorid u koncentraciji od 25 mM do 100 mM.
5. Farmaceutski pripravak prema zahtjevu 3 ili 4, naznačen time što farmaceutski pripravak sadrži natrijev fosfat u koncentraciji od 10 mM do 100 mM.
6. Farmaceutski pripravak prema bilo kojem od zahtjeva 1-5:
(a) pri čemu je polipeptid prisutan u koncentraciji od 1 mg/mL do 400 mg/mL;
(b) koji sadrži pH od 6,5 do 7,5;
(c) pri čemu se polipeptid veže na C5 s ravnotežnom konstantom disocijacije (KD) od 0,1 nM do 1 nM;
(d) pri čemu polipeptid blokira proizvodnju C5a nakon aktivacije alternativnog puta aktivacije komplementa; ili
(e) pri čemu polipeptid blokira formiranje kompleksa napada membrane (MAC) nakon aktivacije klasičnog puta, alternativnog puta ili lektinskog puta aktivacije komplementa.
7. Farmaceutski pripravak prema zahtjevu 6, naznačen time što je polipeptid prisutan u koncentraciji od 40 mg/mL.
8. Farmaceutski pripravak prema zahtjevu 6 ili 7, naznačen time što farmaceutski pripravak sadrži 75,7 mM natrijevog klorida i 50 mM natrijevog fosfata, te pH pripravka iznosi 6,7-7,3.
9. Farmaceutski pripravak prema bilo kojem od zahtjeva 1-8, naznačen time što je za upotrebu kao lijek.
10. Farmaceutski pripravak za upotrebu prema zahtjevu 9, naznačen time što se farmaceutski pripravak primjenjuje potkožno (SC) ili intravenski (IV).
11. Farmaceutski pripravak za upotrebu prema zahtjevu 9 ili 10, naznačen time što subjekt nije koloniziran s Neisseria meningitides.
12. Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 9-11, naznačen time što se subjektu istovremeno daje jedan ili više antibiotika kako bi se smanjio rizik od infekcije s Neisseria meningitides, pri čemu, izborno, jedan ili više antibiotika sadrži ciprofloksacin, pri čemu se, izborno, ciprofloksacin oralno primjenjuje u dozi od oko 100 mg do oko 1000 mg.
13. Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 9-12, naznačen time što se farmaceutski pripravak primjenjuje u kombinaciji s ekulizumabom.
14. Auto-injektorski uređaj, naznačen time što sadrži farmaceutski pripravak prema bilo kojem od zahtjeva 1-8.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562268360P | 2015-12-16 | 2015-12-16 | |
US201662331320P | 2016-05-03 | 2016-05-03 | |
US201662347486P | 2016-06-08 | 2016-06-08 | |
EP20157916.6A EP3685847B1 (en) | 2015-12-16 | 2016-12-07 | Modulators of complement activity |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230182T1 true HRP20230182T1 (hr) | 2023-04-14 |
Family
ID=57758701
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230182TT HRP20230182T1 (hr) | 2015-12-16 | 2016-12-07 | Modulatori aktivnosti komplementa |
HRP20200508TT HRP20200508T1 (hr) | 2015-12-16 | 2020-03-27 | Modulatori aktivnosti i komplementa |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200508TT HRP20200508T1 (hr) | 2015-12-16 | 2020-03-27 | Modulatori aktivnosti i komplementa |
Country Status (25)
Country | Link |
---|---|
US (2) | US10835574B2 (hr) |
EP (3) | EP3685847B1 (hr) |
JP (3) | JP7126940B2 (hr) |
KR (1) | KR20180094913A (hr) |
CN (2) | CN115920000A (hr) |
AU (1) | AU2016370210A1 (hr) |
BR (1) | BR112018012174A2 (hr) |
CA (1) | CA3007772A1 (hr) |
CY (1) | CY1123031T1 (hr) |
DK (2) | DK3685847T5 (hr) |
ES (2) | ES2781551T3 (hr) |
FI (1) | FI3685847T3 (hr) |
HR (2) | HRP20230182T1 (hr) |
HU (1) | HUE061759T2 (hr) |
IL (1) | IL259762B (hr) |
LT (2) | LT3685847T (hr) |
MX (2) | MX2018007352A (hr) |
PL (2) | PL3389692T3 (hr) |
PT (2) | PT3389692T (hr) |
RS (2) | RS64067B1 (hr) |
RU (2) | RU2769701C2 (hr) |
SG (1) | SG11201804721SA (hr) |
SI (2) | SI3389692T1 (hr) |
TW (2) | TWI745320B (hr) |
WO (1) | WO2017105939A1 (hr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS62428B1 (sr) | 2014-06-12 | 2021-11-30 | Ra Pharmaceuticals Inc | Modulacija aktivnosti komplementa |
LT3250230T (lt) | 2015-01-28 | 2021-12-27 | Ra Pharmaceuticals, Inc. | Komplemento aktyvumo moduliatoriai |
EP3685847B1 (en) | 2015-12-16 | 2023-01-11 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
MX2019006527A (es) | 2016-12-07 | 2019-08-01 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
EP3720463A1 (en) | 2017-12-04 | 2020-10-14 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
US20220160820A1 (en) | 2019-03-08 | 2022-05-26 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
CA3137895A1 (en) | 2019-04-24 | 2020-10-29 | Ra Pharmaceuticals, Inc. | Compositions and methods for modulating complement activity |
ES2973767T3 (es) | 2019-06-04 | 2024-06-24 | Ra Pharmaceuticals Inc | Tratamiento de enfermedades inflamatorias con inhibidores del complemento |
BR112022002522A2 (pt) | 2019-09-12 | 2022-08-16 | Ra Pharmaceuticals Inc | Tratamento de doenças neurológicas com inibidores do complemento |
WO2021222549A1 (en) | 2020-04-30 | 2021-11-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
AU2022378567A1 (en) | 2021-10-29 | 2024-04-11 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6361943B1 (en) | 1996-10-17 | 2002-03-26 | Mitsubishi Chemical Corporation | Molecule that homologizes genotype and phenotype and utilization thereof |
US4271068A (en) | 1968-05-10 | 1981-06-02 | Ciba-Geigy Corporation | Process for the manufacture of cystine-containing peptides |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4033940A (en) | 1975-11-12 | 1977-07-05 | Armour Pharmaceutical Company | Cyclization of peptides |
US4216141A (en) | 1978-07-19 | 1980-08-05 | The Salk Institute For Biological Studies | Method for cyclization of peptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5371109A (en) | 1986-07-01 | 1994-12-06 | Drilletten Ab | Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ES2118066T3 (es) | 1989-10-05 | 1998-09-16 | Optein Inc | Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos. |
US5585353A (en) | 1990-02-02 | 1996-12-17 | The Rockefeller University | Antibiotic peptides containing D-amino acids |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US5843701A (en) | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
JPH08510325A (ja) | 1993-05-28 | 1996-10-29 | カイロン コーポレイション | 生物学的に活性なペプチド配列の選択方法 |
PT710243E (pt) | 1993-06-29 | 2000-11-30 | Ferring Bv | Sintese melhorada de peptidos ciclicos. |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5834318A (en) | 1995-05-10 | 1998-11-10 | Bayer Corporation | Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins |
US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
US6720472B2 (en) | 1996-07-12 | 2004-04-13 | University Of Medicine And Dentistry Of New Jersey | HMGI proteins in cancer and obesity |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6348584B1 (en) | 1996-10-17 | 2002-02-19 | John Edward Hodgson | Fibronectin binding protein compounds |
US5922680A (en) | 1996-10-23 | 1999-07-13 | Ferring, B.V. | Stabilized composition for oral administration of peptides |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
DK0971946T3 (da) | 1997-01-21 | 2006-10-30 | Gen Hospital Corp | Selektion af proteiner ved anvendelse af RNA-protein-fusioner |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
EP0896001A1 (en) | 1997-08-08 | 1999-02-10 | Daicel Chemical Industries, Ltd. | Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates |
US6429301B1 (en) | 1998-04-17 | 2002-08-06 | Whitehead Institute For Biomedical Research | Use of a ribozyme to join nucleic acids and peptides |
TR200100366T2 (tr) | 1998-08-07 | 2001-11-21 | Emisphere Technologies, Inc. | Aktif madde dağıtmaya mahsus bileşikler ve bileşimler. |
WO2000021559A2 (en) | 1998-10-09 | 2000-04-20 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
US6962781B1 (en) | 2000-05-19 | 2005-11-08 | Proteonova, Inc. | In vitro evolution of nucleic acids and encoded polypeptide |
US7244701B2 (en) | 2000-06-16 | 2007-07-17 | Zealand Phama A/S | Diuretic peptide conjugate |
US8329169B2 (en) | 2003-05-15 | 2012-12-11 | Genentech, Inc. | Methods and compositions for the prevention and treatment of sepsis |
EP1667702A2 (en) | 2003-09-10 | 2006-06-14 | Baxter International Inc., Baxter Healthcare Corp. | Peptides that inhibit complement activation |
US20050191343A1 (en) | 2003-11-26 | 2005-09-01 | Shire Laboratories, Inc. | Micellar systems useful for delivery of lipophilic or hydrophobic compounds |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
WO2006066258A2 (en) | 2004-12-17 | 2006-06-22 | Neose Technologies, Inc. | Lipoconjugation of peptides |
JP5372380B2 (ja) | 2005-01-24 | 2013-12-18 | ペプスキャン システムズ ベー.フェー. | 結合化合物、免疫原性化合物およびペプチド模倣体 |
EP1874289A2 (en) | 2005-03-29 | 2008-01-09 | Cardax Pharmaceuticals, Inc. | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
CN103505728A (zh) | 2005-05-26 | 2014-01-15 | 科罗拉多大学评议会法人机构 | 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制 |
EP1888031B1 (en) | 2005-06-06 | 2013-01-23 | Camurus Ab | Glp-1 analogue formulations |
HUE026423T2 (en) | 2005-11-04 | 2016-05-30 | Genentech Inc | Use of complement biosynthetic pathway inhibitors for treating eye diseases |
EP2359834B1 (en) | 2006-03-15 | 2016-11-09 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
EP1876183A1 (en) | 2006-07-04 | 2008-01-09 | Technische Universität München | Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins |
ES2557056T3 (es) | 2006-10-10 | 2016-01-21 | Regenesance B.V. | Inhibición del complemento para una mejor regeneración de los nervios |
US7736860B2 (en) | 2006-11-09 | 2010-06-15 | Univeristy Of Massachusetts | Methods of identifying compounds for the treatment of sterile inflammation |
WO2008113834A2 (en) | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
US20100015139A1 (en) | 2008-07-10 | 2010-01-21 | Rekha Bansal | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF |
KR20100014486A (ko) | 2007-04-30 | 2010-02-10 | 알콘 리서치, 리미티드 | 보체 인자 d의 저해제를 사용한 연령 관련 황반변성의 치료 |
MX2009013082A (es) | 2007-06-07 | 2010-01-15 | Genentech Inc | Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento. |
WO2009014633A1 (en) | 2007-07-20 | 2009-01-29 | Trustees Of The University Of Pennsylvania | Method of treating acute respiratory distress syndrome |
KR20150080007A (ko) | 2007-10-02 | 2015-07-08 | 포텐시아 팔마큐티칼스, 인크. | 겔로부터 콤스타틴 유사체의 지속적 운반 |
WO2009067191A2 (en) | 2007-11-16 | 2009-05-28 | The General Hospital Corporation | Methods and compositions for the treatment of hepatitis c virus (hcv) infection |
WO2009121065A2 (en) | 2008-03-28 | 2009-10-01 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
US20100093624A1 (en) | 2008-07-30 | 2010-04-15 | Cosmix Therapeutics Llc | Peptide therapeutics that bind vegf and methods of use thereof |
US20110172126A1 (en) | 2008-09-03 | 2011-07-14 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
FI2894165T3 (fi) | 2008-11-10 | 2023-03-23 | Alexion Pharma Inc | Menetelmiä ja koostumuksia komplementtiin liityvien häiriöiden hoitamiseksi |
AU2009230735B1 (en) | 2009-01-08 | 2010-01-21 | Shane Ramodien | Electronic equipment housing |
CA2777845C (en) | 2009-10-16 | 2017-08-01 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
WO2011057158A1 (en) | 2009-11-05 | 2011-05-12 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
CN111560060A (zh) | 2009-12-16 | 2020-08-21 | 诺沃—诺迪斯克有限公司 | 双酰化glp-1衍生物 |
US9358266B2 (en) | 2010-02-25 | 2016-06-07 | The Trustees Of The University Of Pennsylvania | Treatment of sepsis using complement inhibitors |
EP2563359A1 (en) | 2010-04-30 | 2013-03-06 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
TW201241008A (en) | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
CN105413022A (zh) * | 2011-03-29 | 2016-03-23 | 艾伯维公司 | 自动注射装置中的改进的护罩展开 |
EP3964233A1 (en) | 2011-04-08 | 2022-03-09 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
BR112013028271B1 (pt) * | 2011-05-05 | 2020-11-24 | Wellstat Immuno Therapeutics, Llc | Polipeptideo, acido nucleico, vetor viral, preparação farmaceutica, bem como uso dos mesmos no tratamento de doenqa mediada por complemento |
WO2012162215A1 (en) | 2011-05-20 | 2012-11-29 | The Trustees Of The University Of Pennsylvania | Promotion of fracture healing using complement inhibitors |
WO2012174055A1 (en) | 2011-06-13 | 2012-12-20 | The Trustees Of The University Of Pennsylvania | Wound healing using complement inhibitors |
CN102321170B (zh) | 2011-09-14 | 2013-11-13 | 深圳翰宇药业股份有限公司 | 利拉鲁肽变构体及其缀合物 |
WO2013052736A2 (en) | 2011-10-06 | 2013-04-11 | The Medicines Company | Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010 |
HUE041996T2 (hu) | 2012-02-20 | 2019-07-29 | Swedish Orphan Biovitrum Ab Publ | A C5 humán komplementhez kötõdõ polipeptidek |
US20130246083A1 (en) | 2012-03-16 | 2013-09-19 | Alexion Pharmaceuticals, Inc. | Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor |
WO2013172954A1 (en) * | 2012-05-17 | 2013-11-21 | Ra Pharmaceuticals, Inc | Peptide and peptidomimetic inhibitors |
US9579360B2 (en) | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
US20130345257A1 (en) | 2012-06-26 | 2013-12-26 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
US20150330989A1 (en) | 2012-11-15 | 2015-11-19 | The Brigham And Women's Hospital, Inc. | Method and system for diagnosing and treating preeclampsia |
US9700633B2 (en) | 2013-01-28 | 2017-07-11 | Jenkem Technology Co., Ltd., Tianjin Branch | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof |
US20140234275A1 (en) | 2013-02-15 | 2014-08-21 | Jason Williams | Method for treating als via the increased production of factor h |
US20150057342A1 (en) | 2013-08-21 | 2015-02-26 | Cannabics Pharmaceuticals Inc | Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof |
CN104231085B (zh) * | 2013-09-05 | 2017-03-15 | 复旦大学附属肿瘤医院 | 靶向特异性补体系统抑制剂、其制备方法及应用 |
AU2015233380A1 (en) | 2014-03-20 | 2016-09-08 | Inflarx Gmbh | Inhibitors of C5a for the treatment of viral pneumonia |
RS62428B1 (sr) * | 2014-06-12 | 2021-11-30 | Ra Pharmaceuticals Inc | Modulacija aktivnosti komplementa |
US20160168237A1 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
WO2016118652A1 (en) | 2015-01-21 | 2016-07-28 | Pacira Pharmaceuticals, Inc. | Multivesicular liposome formulations of tranexamic acid |
LT3250230T (lt) * | 2015-01-28 | 2021-12-27 | Ra Pharmaceuticals, Inc. | Komplemento aktyvumo moduliatoriai |
WO2017035362A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
EP3685847B1 (en) | 2015-12-16 | 2023-01-11 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
MX2019006527A (es) * | 2016-12-07 | 2019-08-01 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
EP3682016A4 (en) | 2017-09-11 | 2021-06-02 | RA Pharmaceuticals, Inc. | FORMULATIONS FOR ADMINISTERING COMPOUNDS |
EP3720463A1 (en) | 2017-12-04 | 2020-10-14 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
US20220160820A1 (en) | 2019-03-08 | 2022-05-26 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
CA3137895A1 (en) | 2019-04-24 | 2020-10-29 | Ra Pharmaceuticals, Inc. | Compositions and methods for modulating complement activity |
-
2016
- 2016-12-07 EP EP20157916.6A patent/EP3685847B1/en active Active
- 2016-12-07 CN CN202210878127.8A patent/CN115920000A/zh active Pending
- 2016-12-07 PL PL16823378T patent/PL3389692T3/pl unknown
- 2016-12-07 RU RU2020131790A patent/RU2769701C2/ru active
- 2016-12-07 DK DK20157916.6T patent/DK3685847T5/da active
- 2016-12-07 HU HUE20157916A patent/HUE061759T2/hu unknown
- 2016-12-07 SG SG11201804721SA patent/SG11201804721SA/en unknown
- 2016-12-07 RU RU2018121615A patent/RU2733720C2/ru active
- 2016-12-07 BR BR112018012174-6A patent/BR112018012174A2/pt active Search and Examination
- 2016-12-07 TW TW105140483A patent/TWI745320B/zh active
- 2016-12-07 HR HRP20230182TT patent/HRP20230182T1/hr unknown
- 2016-12-07 SI SI201630688T patent/SI3389692T1/sl unknown
- 2016-12-07 ES ES16823378T patent/ES2781551T3/es active Active
- 2016-12-07 LT LTEP20157916.6T patent/LT3685847T/lt unknown
- 2016-12-07 MX MX2018007352A patent/MX2018007352A/es unknown
- 2016-12-07 JP JP2018531393A patent/JP7126940B2/ja active Active
- 2016-12-07 US US16/062,653 patent/US10835574B2/en active Active
- 2016-12-07 EP EP16823378.1A patent/EP3389692B1/en active Active
- 2016-12-07 PT PT168233781T patent/PT3389692T/pt unknown
- 2016-12-07 RS RS20230218A patent/RS64067B1/sr unknown
- 2016-12-07 WO PCT/US2016/065228 patent/WO2017105939A1/en active Application Filing
- 2016-12-07 EP EP22216383.4A patent/EP4218790A1/en active Pending
- 2016-12-07 RS RS20200350A patent/RS60134B1/sr unknown
- 2016-12-07 ES ES20157916T patent/ES2941640T3/es active Active
- 2016-12-07 PT PT201579166T patent/PT3685847T/pt unknown
- 2016-12-07 FI FIEP20157916.6T patent/FI3685847T3/fi active
- 2016-12-07 CN CN201680081854.4A patent/CN108697759B/zh active Active
- 2016-12-07 PL PL20157916.6T patent/PL3685847T3/pl unknown
- 2016-12-07 AU AU2016370210A patent/AU2016370210A1/en not_active Abandoned
- 2016-12-07 LT LTEP16823378.1T patent/LT3389692T/lt unknown
- 2016-12-07 SI SI201631679T patent/SI3685847T1/sl unknown
- 2016-12-07 DK DK16823378.1T patent/DK3389692T3/da active
- 2016-12-07 CA CA3007772A patent/CA3007772A1/en active Pending
- 2016-12-07 KR KR1020187017156A patent/KR20180094913A/ko not_active Application Discontinuation
- 2016-12-07 TW TW110131918A patent/TWI779805B/zh active
-
2018
- 2018-06-03 IL IL259762A patent/IL259762B/en active IP Right Grant
- 2018-06-14 MX MX2022013454A patent/MX2022013454A/es unknown
-
2020
- 2020-03-27 HR HRP20200508TT patent/HRP20200508T1/hr unknown
- 2020-03-27 CY CY20201100292T patent/CY1123031T1/el unknown
- 2020-10-08 US US17/065,560 patent/US11752190B2/en active Active
-
2022
- 2022-08-17 JP JP2022130131A patent/JP7379615B2/ja active Active
-
2023
- 2023-11-01 JP JP2023187363A patent/JP2024001300A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230182T1 (hr) | Modulatori aktivnosti komplementa | |
CL2013000815A1 (es) | Composicion farmaceutica liquida de adm inistracion parenteral que comprende dexmedetomidina o una sal de la misma en una concentracion de 0,005 a 50 µg/ml y adicionalmente comprende cloruro de sodio en una concentracion de 0,01 a 2 % en peso, dispuesta dentro de un contenedor de vidrio sellado. | |
BR112014022451A2 (pt) | lipídios aminoácido vetorizadores, sistema veículo, seu uso, e composição farmacêutica | |
MA38399A1 (fr) | Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique | |
PH12015502441B1 (en) | Anti-il-4/anti-il-13 bispecific antibody formulations | |
BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
NZ711567A (en) | Antibody formulations | |
JP2015510882A5 (hr) | ||
HRP20180071T4 (hr) | Upotreba kladribina u liječenju očnog neuromijelitisa | |
HRP20201598T1 (hr) | Pripravci | |
MX2019008489A (es) | Tratamiento que comprende la administracion oral o gastrica de edaravona. | |
EA201790223A1 (ru) | Водный препарат, содержащий парацетамол и ибупрофен | |
JP2016515623A5 (hr) | ||
EA201992382A2 (ru) | Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения | |
PH12018500817A1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
BR112015014092A2 (pt) | administração oral transmucosal de acetato de glatirâmer | |
MX2017015202A (es) | Formulaciones liquidas de celecoxib para administracion oral. | |
BR112015014137A2 (pt) | unidade sólida com alto teor de fexofenadina e processo para a preparação da mesma | |
AR090244A1 (es) | Formulacion de anticuerpo anti-selectina p | |
EA201991531A1 (ru) | Способы лечения композициями линаклотида с отсроченным высвобождением | |
BR112015017483A2 (pt) | uso de sais de tungstênio (iv) para o tratamento da infertilidade feminina em mamíferos não diabéticos | |
AR108676A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant | |
AR114162A1 (es) | Composición farmacéutica líquida | |
RU2014106575A (ru) | Способ профилактики кровотечения при миомэктомии |